Security record · archived quarter
ARCT
Arcturus Therapeutics Holdings Inc. · Healthcare · Biotechnology
10Tracked holders
—Δ holders
3.78MShares held
$92.06MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 62 | +4 | 19.18M | $128.95M | +5 | −1 |
| Q1 2026 | 60 | 0 | 18.54M | $142.94M | +4 | −4 |
| Q4 2025 | 60 | 0 | 18.71M | $114.66M | +3 | −3 |
| Q3 2025 | 16 | -1 | 10.27M | $189.25M | +1 | −2 |
| Q2 2025 | 14 | +1 | 8.29M | $107.85M | +2 | −1 |
| Q1 2025 | 10 | +3 | 4.50M | $47.65M | +3 | — |
| Q4 2024 | 7 | -2 | 3.97M | $67.41M | — | −2 |
| Q3 2024 | 8 | -2 | 3.11M | $72.14M | — | −2 |
| Q2 2024 | 10 | — | 3.78M | $92.06M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 1.96M | — | $47.85M | 0.4% | n/c | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 555.02K | — | $13.51M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 546.01K | — | $13.30M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 546.01K | — | $13.30M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 360.75K | — | $8.78M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 360.75K | — | $8.78M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 360.75K | — | $8.78M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 360.75K | — | $8.78M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 360.75K | — | $8.78M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 244.15K | — | $5.95M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 45.22K | — | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 21.63K | — | $526,740 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 21.63K | — | $526,740 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 17.62K | — | $429,000 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 13.32K | — | $324,293 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 11.70K | — | $284,895 | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 11.70K | — | $284,895 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 124 holders, 24.09M shares, $182.18M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API